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Summary Two human cell lines (UACC-812 and 893), both containing significant amplification of the
HER-2/neu gene, were established from biopsy specimens of breast carcinomas. One patient had Stage II
breast carcinoma; the other had metastatic disease. Characterisation of these lines has revealed that both are
highly aneuploid containing multiple clonal chromosome alterations, have doubling times near 100 h, and are
oestrogen and progesterone receptor negative. Electron microscopy demonstrates that both lines contain
numerous microvilli, cytoplasmic filaments, multivesicular bodies, and desmosomes. Immunoblot analysis for
P-glycoprotein using the monoclonal antibody C219 was negative for both patient cell lines. These relatively
rare cell lines may represent a useful model to investigate human breast carcinomas.
Despite intensive efforts over the past 50 years, establishment
of human breast cancer cell lines from breast tumour tissue
has been largely unsuccessful (Smith et al., 1984). Only 12
bona fide characterised cell lines have been reported in the
literature (Table I). The establishment and some characterisa-
tion of the two new breast tumour cell lines - UACC-812
and UACC-893 - has been previously reported (Leibovitz et
al., 1988). The biologic characteristics of these two lines have-
been further analysed with respect to their in vitro growth
properties, cellular ultrastructure, hormone receptor status,
drug sensitivity and cytogenetic profile. Of primary interest,
both cell lines exhibit amplification of the HER-2/neu onco-
gene.
Materials and methods
Patient information
The UACC-812 cell line was derived from a biopsy of the left
breast of a 42-year old women with infiltrating ductal car-
cinoma, grade 2, Stage IV (Figure la). Three years prior to
this biopsy, she was diagnosed as having mammary cancer of
the right breast, refused surgical intervention, and was treat-
ed solely with chemotherapeutic agents (doxorubicin and
cyclophosphamide). Metastases to the right neck occurred 2
years later and the patient was retreated with combination
chemotherapy (5-fluorouracil, doxorubicin and cyclophosph-
amide). A clinical complete response was obtained after six
courses of therapy; however, 8 months after the completion
of therapy, she developed liver metastases and a large mass
in the left breast. The breast tumour was oestrogen receptor
and progesterone receptor negative. Mastectomy was per-
formed and a large tumour mass (6.0 x 6.0 x 8.0 cm) was
removed and an aliquot submitted for tissue culture. DNA
flow cytometry showed aneuploidy with a DNA index of
1.59.
The UACC-893 cell line was derived from an infiltrating
ductal carcinoma of the right breast of a 57-year old women
who had a negative mammogram 11 months prior to diag-
nosis. The tumour, dissected from a lumpectomy, measured
1.8 x 1.0 x 0.8 cm, grade 2 (Figure lb). Four of seven axil-
lary lymph nodes were positive for metastatic disease. This
patient developed metastatic disease and died of disease
within 3 years of diagnosis despite receiving adjuvant chemo-
therapy with doxorubicin, cyclophosphamide and 5-fluorour-
acil. Oestrogen and progesterone receptors were negative and
DNA flow cytometry showed aneuploidy with a DNA index
of 1.72. An aliquot of the primary tumour tissue was submit-
ted for this culture.
Transport medium
Tissue specimens derived from presumed breast carcinomas
were transported to the tissue culture laboratory in medium
L15MI5 (Table II). This detoxification-growth medium pre-
serves tissue viability for at least 4 days (Kischer et al., 1989).
Tissue processing
The tissues were debrided of normal tissue, necrotic areas
and blood clots and placed in a sterile Petri dish containing
about 15 ml of medium Mi5, and processed after the method
of Leibovitz et al. (1976). Specifically, the tissue was sliced
with crossed surgical blades into 1 mm cubes. The medium
surrounding the cubes was harvested for the spillout and
fine-mince cultures (Leibovitz et al., 1976). The remaining
tissue cubes were digested for 2 h in collagenase (0.15%)-
DNAase (0.015%) at 37°C. All harvested cells were washed
at least three times in M15, and cell viability was determined
by the trypan blue exclusion technique.
Media
Medium L15 was modified by lowering the osmolarity from
327 to 300 mOsm by reducing the NaCI concentration from
0.8% to 0.644% and adding 20 mM Hepes and 6.93 mM Tris
buffers (American Biorganics). The addition of detoxification
and/or growth reagents entailed many modifications of LI5
medium and are coded as M-media. The most useful media
to date for establishing both short-term and long-term
growth of tumour cells derived from solid tissues are listed in
Table II. M13 is a relatively simple medium that will main-
tain almost all established cell lines when fortified with
2-5% foetal bovine serum. The addition of detoxification
reagents to M13 yielded M15. Addition of growth reagents
was done in a stepwise fashion, i.e., addition of pituitary
growth factor to M15 produced M19; oestradiol to M19
yields M33; addition of epidermal growth factor to M33
yields M41. the osmolarity of M41 is 323 mOsm. Depending
on the viable tumour-like cell yield, tissue cells were explant-
ed in the most complex medium first. When sufficient cells, at
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Table I Characterised human breast carcinoma cell lines established from primary breast tumours
Hormone Cell doubling
Year receptors Type of time Modal Age of
Cell line established Reference ED PI tumour (h) Number Metastasis patient
BT-20 1958 Lasfargues et al., 1958 - - IDCC 30 NDd ND 74
CaMa 1959 Dobrynin, 1963 ND ND Scirrhous ND 62-45 + 28
BTM-1 1968 Martorelli et al., 1969 ND ND Scirrhous 20 ND ND 42
BOT-2 1975 Norquist et al., 1975 ND ND IDC 16-18 63 ND 31
BT-410 1977 Lasfarques et al., 1978 - + IDC 72 65 ND 60
BT-474 1977 Lasfarques et al., 1978 - + IDC 120 72 ND 25
Hs578T 1977 Hackett et al., 1977 - - IDC 24-30 58 ND 74
YMB-1 1984 Yamane et al., 1984 + + IDC 44 73 + 55
CAL 18A 1985 Gioanni et al., 1985 - - ND 15 71 + 46
CAL 18B 1985 Gioanni et al., 1985 - - ND 30 65 + 46
VHB-1 1984 Vanderwalle et al., 1987 + + IDC 30 70-74 + 74
UACC 812 1988 This report - - IDC 100 58-64 + 42
UACC 893 1988 This report - - IDC 120 62 + 57
8701-BC 1989 Minafra, 1989 ND ND IDC 28.8 55-60 + 72
'E = oestrogen receptors; bp = progesterone receptors; CIDC = infiltrating ductal carcinomas; dND = not determined by author;eCarcinosar-
coma; +: metastasis to lymph nodes and/or other body tissues.
re q91# XIWX
Figure 1 a, In 1986, this 43-year old women underwent a simple left mastectomy for a central 8 x 6 x 6 cm non-circumscribed
malignancy. Inflammatory carcinoma was clinically suspected and confirmed by breast skin biopsy which showed dermal lymphatic
permeation by neoplasm (Stage IV). The large mass was a grade 2 infiltrating ductal carcinoma with extensive desmoplasia and
scattered areas ofmucin production. Vascular involvement occurred. Regional lymph nodes were not resected. The aneuploid DNA
index was 1.59. Haematoxylin and eosin stain. b, In 1987, this 58-year old women underwent a right modified radical mastectomy.
The neoplasm was 1.8 x 1.8 x 0.8 cm, non-circumscribed. Microscopically it was a grade 2 infiltrating ductal carcinoma. Level III
axillary lymph nodes were four positive of seven. The aneuploid DNA index was 1.72. Haematoxylin and eosin stain.
Magnification to print 636 x.BREAST CANCER CELL LINES 729
Table II Modifications (M) ofmedium L-15
Mediums M-13, M-15, M-19, M-33 and M-41
MediumM-13
Final weight Volume ofstock
Ingredient Stock solution per litre solution per litre
L-15 medium modifieda I litre pkg
(American Biorganics)
Hydrocortisoneb 10-5 M 3.60 mg 1.0ml
Insulin, bovine 1.0% 10.00mg 1.0ml
pancreas
Transferrin 1.0% 10.00 mg 1.0ml
Glutamine 2.92% 292.00 mg 10.0 ml
Antibiotics (100 x) 10.0 ml
Additionsfor Medium M-15 to M-13
Detoxification reagents
Sodium selenite 10-5 M 1.73 jug 1.0 ml
Glutathione, reduced 0.3% 15.00mg 10.0ml
Catalase 0.5% 5.00 mg 1.0 ml
(l1,000 U mg-1)
Methyl cellulose 2.0% 2.00 mg 100.0 ml
15 CPS
Polyvinylpyrollidone-360 5.0% 1.00 mg 20.0 ml
Growth reagents
2-Mercaptoethanol 10-5 M 0.80 mg 1.0 ml
Orotic acid 0.3% 15.00mg 5.0 ml
DL-Ornithine 0.3% 15.00 mg 5.0 ml
Additionfor Medium M-19 to M-15
Whole bovine pituitary 20.0% 2.5 ml
Extractc
Additionfor M-33 to M-19
Oestradiol 10-5 M 0.003 mg 1.0 ml
Additionsfor M-41 to M-33
Proline 20 mM 23.00 mg 10.0 ml
Thyroxine 10-6 M 0.0008 mg 1.0 ml
O-Phosphoryl- 5 x 10-'M 70.00mg 1.0 ml
ethanolamine
EGFd 10 tgml-' 10ig 1.0ml
aL-15 medium modified by reduction ofNaCI from 0.8% to 0.644%
and adding 20mM hepes buffer and 6.93 mM tris buffer. Osmolarity is
300 mOsm. Addition of detoxification and growth reagents raises
osmolarity to 322mOsm. *All ingredients but methocel and PVP-360
are combined and filtered sterilised. Methocel and PVP-360 are
autoclaved and thenaddedaseptically. bAll ingredients arefrom Sigma,
St Louis, except as indicated. cPel-Freez, Rogers, AR, dBachem Inc,
Torrance, CA.
least 5 x 105 per flask, were obtained, all media were com-
pared for both short-term and long-term growth. When long-
term growth was obtained, medium M13 with 2-5% foetal
bovine serum (FBS) usually sufficed. Medium L15 with
5-10% FBS (readily available from commercial sources)
yields excellent growth for the established cell lines.
Tissue cell culturing
As the media are bicarbonate and glucose free, all culturing
could be done in closed systems (screw capped flasks; Falcon)
in a regulator incubator at 36-37C with minimal fluctua-
tions in pH. Initial explants were made on collagen coated
flasks [after the method of Macklis et al. (1985)].
Flasks were examined daily for the first week. Those
containing tumour cells in suspension were harvested by
centrifugation and re-seeded in a fresh collagen-coated screw
capped flask. One or more of the flasks containing tumour-
like cells were sacrificed within 7 days for cytogenetic studies;
the rest were retained for long-term growth studies. Flasks
containing moderate to large numbers of tumour-like cells
were fed once per week. Those containing small numbers of
tumour-like cells were not refed, but had 1 ml of fresh media
added per week until growth started.
Geneticin eradication offibroblasts
Flasks containing tumour-like cell colonies firmly attached to
the plastic and contaminated by fibroblast outgrowth were
refed with M15 containing 100 tgml1' Geneticin (Sigma
#6-5013) for 3 days [after the method of Halaban and
Alfano (1984)]. The antibiotic was then removed, the mono-
layer washed with Dulbecco's basic salt solution (Irvine
Scientific) and then refed with the medium under study.
Flow cytometric DNA quantitation
Fresh neoplasm was cut into 1 mm slices and fixed in 3:3:4
(proportions of methanol, glacial acetic acid and distilled
water). Pieces were minced with crossed scalpels, then incu-
bated overnight at 37°C in 2 ml PBS-A containing 0.2%
trypsin, 0.1% EDTA, and 200 uml1 collagenase type IV.
The suspension was repeatedly syringed gently through a
26-gauge needle and filtered through 30 l.m mesh before
resuspending in 1 ml PBS-A containing 1 mg RNAase, 1%
NP-40, and 10 mg propidium iodide for 30min. Immediately
prior to analysis, 10 ml of freshly thawed chicken erythro-
cytes (CRBC) were added as control.
DNA content was measured using a Coulter EPICS V flow
cytometer fitted with a coherent 5-W argon laser fluorescing
at 488 nm. Approximately I04-I05 cells were analysed in
each case. The DNA index (DI) was calculated as the ratio
of sample peak channel number to CRBC, divided by the
external standard to CRBC ratio.
Generation time and cellpassage
The mathematical technique of Hayflick (1973), as modified
by Leibovitz et al. (1976), was used to obtain the generation
time of each cell line. All subcultures were 1:2 splits using
0.25% trypsin - 0.1% EDTA in Dulbecco's basic salt solu-
tion without calcium or magnesium (Irvine Scientific).
Electron microscopy
In preparation for transmission electron microscopy (TEM),
cells were rinsed in 0.2M phosphate buffer, immersed in
modified Karnovsky's fixative for 1 h, rinsed again in phos-
phate buffer, and post-fixed in 2% osmium tetroxide for
45 min in the dark. Subsequently, cells were rinsed in phos-
phate buffer, dehydrated in increasing concentrations of
ethanol, and embedded in Spurr resin. Ultrathin sections
were cut on a Porter-Blum MT-2B ultramicrotome, stained
with uranyl acetate and Reynold's lead solution, and examin-
ed using a Philips 300 transmission electron microscope
(operating at 60 KV accelerating voltage).
Oestrogen andprogesterone receptors
Cell pellets were prepared and stored in - 80°C. A cytostolic
extact was obtained from passage 5 on UACC-812 and pas-
sage 9 on UACC-893 and analysed as previously described
(Kute et al., 1980). Results are reported in femtomoles per
mg of protein and results were defined as positive if there
was >10 femtomolemg-I of protein and the affinity con-
stant was >5 x 108 M-1. Positive and negative cytosolic
material was analysed at the same time for quality control.
Histochemistry
Tissue cells were grown on coverslips, washing in PBS for
5 min, fixed in cold methanol for 5 min, and then in acetone
for 5 s to assure permeabilisation. After 5 additional min in
PBS, the cells were incubated with the desired antibody for
30 min, washed in PBS for 5 min and then incubated with
fluorescinated goat anti mouse IgG (Cappel, Durham NC)
for 30 min. Coverslips were then washed with PBS, mounted
and observed with a Zeiss epifluorescent microscope. Anti-
bodies were anticytokeratins KAI and KA4 (Nagle et al.,
1986), anticytokeratin 10.11 (Chan et al., 1986), anti-vimentin
(Dako) and anti-HER-2 (Triton Biosciences). UACC was
studied at passage 36 and UACC 893 was studied at passage
9.730 P. MELTZER et al.
Cytogenetics
Exponentially growing cultures were harvested for karyotypic
analysis, slides prepared, and Q- or G-banding performed as
previously described (Trent & Thompson, 1987). >50 cells
per cell line were analysed, with results expressed according
to ISCN recommendations (1985).
Immunoblot analysis
Plasma membrane preparations from UACC 812 and UACC
893 were prepared according to the method of Riordan and
Ling (1979). Cell lines known to be negative (8226/S) and
positive (8226/Dox4O) for over expression of P-glycoprotein
wre used as controls (Dalton et al., 1986). Polyacrylamide gel
electrophoresis was performed according to the method of
Fairbanks et al. (1971) with slight modification (Delenham et
al., 1982). The procedure of Towbin et al. (1979) was used to
transfer proteins from the gel to nitrocellulose paper which
was then probed with the monoclonal antibody C-219 (Cen-
tocor). '251-rabbit anti-mouse IgG (New England Nuclear
Corp.) was used as a second antibody for detection by
autoradiography.
In vitro drug sensitivity testing
A modified protein detection system was used to calculate
cell survival following exposure to chemotherapeutic drugs
(Bradford et al., 1976). Single cell suspensions of the cell lines
obtained in the exponential phase of cell growth were placed
in the M-3 growth medium (Leibovitz, 1985) and plated at
30,000 cells/well in 96-well plates. Following a 5 day incuba-
tion with varying doses of drug, the media plus drug was
aspirated from individual wells. Fifty itl of H20 was then
added to each well, and after three freeze thaw cycles, 200 gl
of Bio-Rad Protein Assay Reagent (Bio-Rad Laboratories)
diluted 1:5 was added to each well. The absorbance of each
well was read at 595 nm using a Dynatech MR600 micro-
plate reader (Dynatech Laboratories). Controls included
medium plus the highest drug concentration and cells with
medium only. The percentage of survival was calculated by
dividing the absorbance of drug treated cells by the absor-
bance of control cells.
Isolation ofDNA and Southern blotting
High molecular weight genomic DNA was isolated by SDS-
proteinase K lysis, organic extraction, and NaCI-ethanol
precipitation (Maniatis et al., 1982). The DNA was quanti-
tated by the 4, 6-diamine 2-phenylindole dihydrochloride
method (Kapuscinski & Skoczylas, 1977). Ten ig of DNA
was digested with HindIII, electrophoreses in 0.8% agarose,
and transferred to a Gene Screen membrane (Southern,
1975). Membranes were hybridised with the 440bp Kpnl-
Xbal fragment of HER-2, pKX044 (kindly provided by T.
Yamamoto, University of Tokyo) labelled by the method of
Feinberg and Vogelstein (1984).
Results
DNAflow cytometry
Both neoplasms were aneuploid; the original breast tumour
tissue and cell lines were in agreement; UACC-812 had a
DNA index of 1.59, UACC-893 DNA index was 1.72.
Establishment ofcell lines
The UACC-812 biopsy specimen yielded 1.8 x I07 viable cells
and growth was obtained on all media (MI9, 33 and 41)
tested; the best growth was on medium 41 which was used to
establish the cell line. However, by the 6th passage, the cells
could be maintained on M13, 5% FBS or L15, 5% FBS.
Aliquots were frozen down under liquid nitrogen in 2nd, 5th,
10th, 15th and 20th passages. There was minimal stromal
contamination, and cells were first subcultured in 3 weeks.
The UACC-893 biopsy specimen yielded 2.1 x 106 viable
cells. Initial tumour-like epithelial cells were evident in the
initial outgrowth of all media tested (M15, 19, 41, 49, 50, 51,
52) but degenerated in all flasks except in one (M41) where a
few colonies persisted and started to proliferate. Fibroblast-
like cells started to overgrow the tumour colonies, but were
eradicated by geneticin treatment. It required 4 months
before these cells could be successfully subcultured. Cells
were frozen down in the 3rd, 6th, 7th, 10th, 15th and 20th
passages. By the 9th passage, the less complex medium M19
could readily be used for maintenance, but the cells still
required pituitary extract for optimal growth. By the 13th
subculture, M13 or L15, with 10% foetal bovine serum
sufficed.
By light microscopy, both cell lines demonstrate an epithe-
lioid morphology in vitro (including distinct nuclei and
nucleoli and a cobblestone 3-dimensional growth) that is
retained throughout numerous subcultures (Figure 2). Both
UACC-812 and UACC-893 grow as slowly expanding col-
onies with defined boundaries. Cells at confluence grow
predominantly 3-dimensionally as monolayers with multi-
layering. Occasionally, there was doming of cells. The cell
a
Figure 2 Morphology: both UACC-812 and UACC-893 grow as
slowly expanding colonies of epithelial-like cells. a, light micro-
scopy and b, phase microscopy of cell line UACC-812. c, Light
microscopy of cell line UACC-893. Final magnification 160 x.BREAST CANCER CELL LINES 731
doubling time for UACC-812 is 100 h, while the UACC-893 P-glycoprotein at a detectable level using this assay (data not
cell line displays a doubling time of 120 h. Both cell lines shown).
have now been subcultured >50 times.
Electron microscopy
Ultrastructural analysis of both cell lines further documents
the epithelioid nature of both cell lines (Figure 3). Electron a .6; ,l ,i;}
microscopy performed at passage 6 for UACC-812 and pas-
sage 13 for UACC-893 demonstrated specialised junctions,
including desmosomes as well as cytoplasmic filaments,
multivesicular bodies, and prominent surface microvilli.
Histochemistry
UACC-812 (passage 36) and UACC-893 (passage 9) had
identical reactivity on immunohistochemical analysis (Table
III). Both were vimentin negative, diffusely positive for cyto-
keratin, and HER-2 positive.
Oestrogen andprogesterone receptors
A portion of the biopsy sampled and cultured cells (from OWNt passages 5 and 9 of UACC-812 and passage 13 of UACC-
893) were submitted for oestrogen and progesterone receptor
analysis. Scatchard analysis performed on both patient
biopsy samples demonstrated the primary tumours to be x - i :
negative for ER and PR, a finding consistent with that
observed for both tumour cell lines (data not shown).
Cytogenetics
Chromosome banding analysis was performed on the initial
outgrowth on UACC-812 within 7 days of explanting and
repeated at 3rd and 10th passage with similar findings.
UACC-893 cytogenetics are from the original outgrowth
within 7 days of explanting. Figures 4 and 5 document the
unique karyotypic features of both tumours, confirming the
independent origin of both lines. Both lines predominantly
display cells with a near triploid modal chromosome number C
and numerous clonal structural chromosome abnormalities.
The modal chromosome number of the UACC-893 cell line
was 62, with a range of 51-65 chromosomes per cell. The
karyotype (Figure 4) was characterised by numeric altera-
tions (most notably chromosome loss) and the presence of
seven unidentifiable marker chromosomes. Clonal structural
alterations included: t(l;3)(pl l;pl1); t(l;7)(pl3;ql 1); iso(6p);
del(6)(q23); iso(7q);del(1l)(pl3); and t(ll;'?)(pl4;?).
The karyotype of UACC-812 demonstrated a modal range
of 58-64 and displayed numerous numeric and structural
changes. As illustrated in Figure 5, the presence of multiple
unidentifiable marker chromosomes, rings, and an abnormal
chromosome 3 (-2.2 x the side of a normal 3) were
observed. This latter chromosome was formed from the t-
generation of an abnormally banding region on chromosome d
3p. Clonal structural changes for UACC-812 included: del(2) ....¢IO,
(q24); t(2;?)(q37;?); HSR(3)(p21); del(7)(q22);t(7;?)(q36;?);
iso(8q); del(9)(pl3); del(ll)(p13); t(21;?)(q22;?).
HER-2/neu amplification
Figure 6 shows a Southern blot of HindIII digested DNA
from normal placenta and the UACC-812 and UACC-893
cell lines, and evidence for HER-2/neu amplification can be
seen in DNAs from both tumour cell lines. The degree of
amplification was estimated as -15-fold for UACC-812 and *i
-20-fold for UACC-893 relative to placental DNA by
Southern blotting of serial dilutions of tumour cell line
DNA.
P-glycoprotein Figure 3 Electron microscopy of UACC-812 a & b and UACC-
893 c & d. Both cell lines demonstrated an ultrastructure profile Both cell lines were examined for the presence of P-glyco- consistent with breast epithelium including desmosomes (D);
protein using immunoblot analysis and the monoclonal anti- cytoplasmic filaments (CF); multivesicular bodies (MF); pseudo-
body C-219. Neither UACC-812 nor UACC-892 produced inclusion (PI); and microvilli (V).732 P. MELTZER et al.
Table III Histochemical results
Cytokeratins Cytokeratins Cytokeratins
5 and 14a 14, 15, 16 19b 8 and 18c Vimentin c-erbB-2
UACC 812 Negative 4 + diffuse 4 + diffuse Negative Positive
UACC 893 Negative 4 + diffuse 4+ diffuse Negative Positive
aAntibody KAl; 'Antibody KA4; CAntibody 10.11.
Figure 4 Giemsa-banded karyotype from UACC-893. A possible HSR can be seen on the second unidentifiable marker
chromosome at the bottom of the karyotype.
Drug sensitivity
Figure 7 shows the cell survival curves for the two patient
cell lines, compared to the well-known breast cancer cell line,
MCF-7, when continuously exposed to the chemotherapeutic
drug doxorubicin. Both patient cell lines were relatively resis-
tant to this drug compared to the MCF-7 cell line.
Discussion
Cell lines from breast tissue are among the most difficult to
establish in tissue culture (Table I). We describe here two
new breast carcinoma cell lines - UACC-812 and UACC-893
- both of which display amplification of the HER-2/neu
gene. Both cell lines display morphology consistent with
breast carcinoma, including ultrastructural features such as
desmosomes and prominent surface microvilli. Both lines
express cytokeratins, confirming their epithelial derivation.
Also, both are hormone receptor negative, a feature held in
common with the overwhelming majority of breast carcin-
oma cell lines established to date (Table I). Both lines carry
amplified copies of the HER-2/neu gene and express the
HER-2/neu protein. The frequent finding of HER-2/neu
amplification in human breast cancers has recently been dem-
onstrated (Slamon et al., 1987) and amplification of this gene
has been suggested
outcome.
to play an important role in clinical
Finally, despite recent reports of P-glycoprotein expression
in clinical patient samples (Salmon et al., 1989), the two lines
we have established failed to significantly express this pro-
tein. Cell line UACC-893 was derived from a patient with
primary Stage II breast cancer, whereas UACC-812 was
obtained from a patient with recurrent metastatic disease,
Stage II, grade IV, who had received extensive prior cyto-
toxic chemotherapy. It is possible that alternate mechanisms
of multidrug resistance (Slovak et al., 1988; Mirski et al.,
1987; Batist et al., 1986) may be responsible for the relative
drug resistance observed in vitro and the clinical drug resis-
tance observed for the patient with Stage IV disease (UACC-
812). Alternatively, it is equally possible that the long
duration of cell culture required prior to cell passage and
analysis for both lines eliminated cells differentially express-
ing P-glycoprotein.
The success rate of establishing cell lines from tumours in
breast tissue has not progressed significantly since Lasfargues
and Ozello established the first one over 30 years ago (1958).
Only 13 additional cell lines have been added in spite of
intensive effort by many investigators (Table I). The common
features of all established cell lines including ours are: all are
hyperdiploid; when determined by the authors, all had metas-BREAST CANCER CELL LINES 733
Figure 5 Representative G-banded karyotype from UACC-812 showing 3pHSRand other clonal structural and numeric abnor-
malities. Ring chromosomes at the bottom of the karyotype are from other cells but were a clonal change in a small sideline
population.
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Figure 6 Southern blot of HindIII cleaved DNA from UACC-
812 and UACC-893 demonstrates amplification of the HER-2/
neu gene relative to human placenta (HP). Ten lag of DNA was
loaded in each lane and the blot was hybridised with the HER-2/
neu probe pKX044.
tasised in vivo; and the tumour tissue released viable tumour
cells in relatively large numbers for culture.
In our laboratory, only these two out of about 100 pri-
mary breast specimens have resulted in established cell lines.
Figure 7 Cytotoxicity curves for the patient cell lines UACC-812
and UACC-893 compared to the breast cancer cell line MCF-7
when exposed to increasing doses of doxorubicin.
However, more than 80% of the specimens yielded <1 x 106
total viable cells (stromal and tumour cells). Most of these
were in a milieu ofdead and dying cells; the average viability
of cell yields was about 20% with a range of < 1% to 50%.
Short-term cultures were obtained in approximately 80% of
specimens. Typical adenocarcinoma-type islands ofepithelial-
like cells which were present in most instances, were useful
for obtaining cytogenetic studies shortly after explantation,
but invariably these died out within a few weeks. The speci-
mens yielding cell lines were from fairly large tumours
(UACC-812 had over 107 viable tumour cells and UACC-893
had over 106 viable tumour cells).734 P. MELTZER et al.
Three other cell lines (Table I) - VHB-1 (Vandewalle et al.,
1987), CAL 18A and CAL 18B (Gioanni et al., 1985) - were
derived from patients with a similar clinical history as our
UACC-812. The patients refused surgical intervention for
their original tumour and were treated by radiation and/or
chemotherapy with clinical remission. However, after about 2
years, relapses occurred with carcinomas developing in the
same breast or the other breast as well as metastasis to other
sites. These tumour cells adapted readily to in vitro growth
and cell lines were established with little difficulty.
Our experience in establishing the UACC-893 cell line
duplicates the findings of Lasfargues et al. (1978) for BT-474
and Yamane et al. (1984) for YMB-1. Although tumour-like
cells were evident on original explants, most of them died out
and the cell lines were established from small clusters of
tumour cells that persisted and finally started to proliferate.
Four to 5 months elapsed before a successful subculture
could be made.
Kraus et al. (1987) found four of 11 established breast cell
lines to have HER-2/neu amplification. These included one
of three cell lines derived from breast tissue (BT474) and
three of eight from pleural fluid (SK-BR-3, MDA-MB-361
and MDA-MB-453). This -33% rate correlates reasonably
well with studies done in primary tissue (Slamon et al., 1987;
Berger et al., 1988).
In conclusion, our experience describes the successful
establishment of two breast carcinoma cell lines. Because of
the potential importance of the HER-2/neu gene to the
biology (and clinical course) of breast cancer, these lines may
represent a useful model to investigate the pathogenesis of
this disease. These cultures will be transmitted to the
American Type Culture Collection for distribution to inter-
ested investigators.
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